235 East 42nd Street
United States - Map
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. The companys Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimers disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The companys Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company primarily offers biopharmaceutical products, including Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
|Pfizer Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 3. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 6; Compensation: 1.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Ian C. Read ,
Chairman, Chief Exec. Officer and Chairman of Exec. Committee
|Mr. Frank A. D'Amelio ,
Chief Financial Officer and Exec. VP of Bus. Operations
|Prof. Mikael Dolsten Ph.D.,
Pres of Worldwide R&D
|Mr. Geno J. Germano ,
Group Pres of Global Innovative Pharma Bus.
|Mr. John D. Young ,
Group Pres of Global Established Pharma Bus.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|